Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

NCT01653379 is registered in ClinicalTrials.gov with Deltanoid Pharmaceuticals as lead sponsor.

NCT NCT01653379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01653379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Lead sponsor
Deltanoid Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
July 31, 2014
Enrollment
42 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism